Vaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average - What's Next?

Shares of Vaxart, Inc. (NASDAQ:VXRT - Get Free Report) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.52 and traded as low as $0.40. Vaxart shares last traded at $0.44, with a volume of 1,691,828 shares changing hands.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on VXRT shares. Wall Street Zen upgraded Vaxart to a "hold" rating in a research note on Thursday, May 22nd. B. Riley cut their price objective on Vaxart from $2.50 to $2.00 and set a "buy" rating on the stock in a research note on Thursday, March 27th.

Vaxart Trading Up 8.7%

The stock has a market cap of $100.72 million, a price-to-earnings ratio of -1.63 and a beta of 1.14. The stock has a fifty day simple moving average of $0.46 and a 200-day simple moving average of $0.52.

Vaxart (NASDAQ:VXRT - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.07). Vaxart had a negative net margin of 122.63% and a negative return on equity of 91.89%. The firm had revenue of $20.88 million for the quarter, compared to the consensus estimate of $2.85 million. Sell-side analysts forecast that Vaxart, Inc. will post -0.39 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Vaxart news, insider Steven Lo bought 100,000 shares of Vaxart stock in a transaction that occurred on Monday, May 19th. The stock was acquired at an average price of $0.49 per share, for a total transaction of $49,000.00. Following the completion of the acquisition, the insider owned 100,000 shares of the company's stock, valued at $49,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.90% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Jones Financial Companies Lllp lifted its holdings in Vaxart by 276,364.7% during the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock worth $196,000 after purchasing an additional 478,111 shares during the last quarter. Squarepoint Ops LLC increased its holdings in Vaxart by 95.0% in the 4th quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company's stock valued at $342,000 after buying an additional 251,789 shares during the period. Raymond James Financial Inc. bought a new position in Vaxart in the fourth quarter valued at approximately $129,000. Virtu Financial LLC bought a new position in shares of Vaxart in the 1st quarter valued at $56,000. Finally, Silverarc Capital Management LLC raised its stake in Vaxart by 7.8% during the fourth quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company's stock worth $714,000 after acquiring an additional 77,782 shares in the last quarter. 18.05% of the stock is currently owned by institutional investors.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.